RT Journal Article
SR Electronic
T1 Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.30.21254540
DO 10.1101/2021.03.30.21254540
A1 Aneesh Chandran
A1 Joshua Rosenheim
A1 Gayathrie Nageswaran
A1 Leo Swadling
A1 Gabriele Pollara
A1 Rishi K Gupta
A1 Jose Afonso Guerra-Assuncao
A1 Annemarie Woolston
A1 Tahel Ronel
A1 Corrina Pade
A1 Joseph Gibbons
A1 Blanca Sanz-Magallon Duque De Estrada
A1 Marc Robert de Massy
A1 Matthew Whelan
A1 Amanda Semper
A1 Tim Brooks
A1 Daniel M Altmann
A1 Rosemary J Boyton
A1 Áine McKnight
A1 Charlotte Manisty
A1 Thomas Alexander Treibel
A1 James Moon
A1 Gillian S Tomlinson
A1 Mala K Maini
A1 Benjamin M Chain
A1 Mahdad Noursadeghi
A1 COVIDsortium Investigators
YR 2021
UL http://medrxiv.org/content/early/2021/04/01/2021.03.30.21254540.abstract
AB The correlates of natural protective immunity to SARS-CoV-2 in the majority who experience asymptomatic infection or non-severe disease are not fully characterised, and remain important as new variants emerge. We addressed this question using blood transcriptomics, multiparameter flow cytometry and T cell receptor (TCR) sequencing spanning the time of incident infection. We identified a type 1 interferon (IFN) response common to other acute respiratory viruses, and a cell proliferation response that discriminated SARS-CoV-2 from other viruses. These responses peaked by the time the virus was first detected, and in some preceded virus detection. Cell proliferation was most evident in CD8 T cells and associated with rapid expansion of SARS-CoV-2 reactive TCRs. We found an equally rapid increase in immunoglobulin transcripts, but circulating virus-specific antibodies lagged by 1-2 weeks. Our data support a protective role for rapid induction of type 1 IFN and CD8 T cell responses to SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for COVIDsortium was donated by individuals, charitable Trusts, and corporations including Goldman Sachs, Citadel and Citadel Securities, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH Charity. RKG is funded by National Institute for Health Research (DRF-2018-11-ST2-004). JCM, CM, and TAT are directly and indirectly supported by the University College London Hospitals (UCLH) and Barts NIHR Biomedical Research Centres, and through the British Heart Foundation (BHF) Accelerator Award (AA/18/6/34223). TAT is funded by a BHF Intermediate Research Fellowship (FS/19/35/34374). MN is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to UCL and UCLH. RJB/DMA are supported by UKRI/MRC Newton (MR/S019553/1, MR/R02622X/1, MR/V036939/1MR/S019553/1, and MR/R02622X/1), NIHR Imperial Biomedical Research Centre (BRC):ITMAT, Cystic Fibrosis Trust SRC, and Horizon 2020 Marie Curie Actions. MKM is supported by the UKRI/NIHR UK-CIC grant, a Wellcome Trust Investigator Award (214191/Z/18/Z), and a CRUK Immunology grant (26603) AM is supported by Rosetrees Trust, The John Black Charitable Foundation, and Medical College of St Bartholomew Hospital Trust. Funders had no role in study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit for publication. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by a UK Research Ethics Committee (South Central - Oxford A Research Ethics Committee, reference 20/SC/0149). All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOpen access to RNAseq and TCRseq data and associated essential metadata will be made available after peer-reviewed publication. Applications for access to the individual participant de-identified data (including data dictionaries) and samples can be made to the access committee via an online application https://covid-consortium.com/application-for-samples/. Each application will be reviewed, with decisions to approve or reject an application for access made on the basis of (i) accordance with participant consent and alignment to the study objectives (ii) evidence for the capability of the applicant to undertake the specified research and (iii) availability of the requested samples. The use of all samples and data will be limited to the approved application for access and stipulated in the material and data transfer agreements between participating sites and investigators requesting access.